We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03278925
Recruitment Status : Active, not recruiting
First Posted : September 12, 2017
Last Update Posted : September 30, 2022
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase I trial studies the side effects and best dose of defined green tea catechin extract and to see how well it works in preventing liver cancer in participants with cirrhosis. Higher levels of the molecule gamma-OHPdG may be found in participants with cirrhosis, which may mean a higher risk of the development of liver cancer. Defined green tea catechin extract may work better to lower levels of gamma-OHPdG and prevent the development of liver cancer.

Condition or disease Intervention/treatment Phase
Cirrhosis Drug: Defined Green Tea Catechin Extract Other: Laboratory Biomarker Analysis Other: Pharmacological Study Other: Questionnaire Administration Phase 1

Detailed Description:


I. To establish maximum tolerated dose (MTD) and to collect safety data of defined green tea catechin extract (Polyphenon E/epigallocatechin gallate [EGCG]) treatment in participants with cirrhosis.

II. To determine the effects of Polyphenon E/EGCG treatment on the suppression of gamma-hydroxy-1,N(2)-propanodeoxyguanosine (gamma-OHPdG) levels in cirrhotic liver.


I. To collect Polyphenon E/EGCG pharmacokinetic data in participants with cirrhosis.

II. To study the correlation between gamma-OHPdG levels and mutation frequency and deoxyribonucleic acid (DNA) damage spectrum in the p53 and beta-catenin genes in cirrhotic liver tissue.

III. To estimate the fraction of participants with liver cirrhosis that have high levels of gamma-OHPdG.


I. To assess the effects of Polyphenon E/EGCG on the grade of cirrhosis as measured by FibroScan and Fibrosis-4 (FIB-4) score.

II. To develop a liquid chromatography-mass spectrometry (LC-MS) and/or enzyme-linked immunosorbent assay (ELISA)-based method for detecting urinary and blood gamma-OHPdG, to correlate with liver gamma-OHPdG levels.

III. To evaluate any hepatocellular carcinoma (HCC) development during the treatment.

OUTLINE: This is a dose-escalation study.

Participants receive defined green tea catechin extract orally (PO) once daily (QD) or twice daily (BID) for 24 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study intervention, participants are followed up at 28 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase I Single-Arm, Multicenter Pilot Study Aimed at Validating γ-OHPdG as a Biomarker and Testing the Effects of Polyphenon E on Its Levels in Patients With Cirrhosis
Actual Study Start Date : August 9, 2018
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : September 30, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Prevention (defined green tea catechin extract)
Participants receive defined green tea catechin extract PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Defined Green Tea Catechin Extract
Given PO

Other: Laboratory Biomarker Analysis
Correlative studies

Other: Pharmacological Study
Correlative studies

Other: Questionnaire Administration
Ancillary studies

Primary Outcome Measures :
  1. Maximum tolerated dose of Polyphenon E [ Time Frame: Up to 4 weeks ]
    Will be defined as the dose at which =< 1 subjects out of 6 experiences a grade 3 or higher toxicity based on Common Terminology Criteria for Adverse Events (CTCAE) criteria.

  2. Change in gamma-OHPdG expression in cirrhotic liver [ Time Frame: Baseline up to 24 weeks ]
    Will be assessed by immunohistochemistry (IHC). Will use a nonparametric Wilcoxon test to compare the post-pre differences to zero.

Secondary Outcome Measures :
  1. Fraction of patients with liver cirrhosis that have high levels of gamma-OHPdG [ Time Frame: Up to 24 weeks ]
    Will use descriptive statistics.

  2. Change in mutation frequency in cirrhotic liver tissue [ Time Frame: Baseline up to 24 weeks ]
    The mutation frequencies will be correlated with the change of gamma-OHPdG level in liver tissue. Will use graphics and a nonparametric correlation measure such as Spearman's correlation.

  3. Polyphenon E pharmacokinetic data in blood and urine in patients with cirrhosis [ Time Frame: Prior to and at 1.5, 3.5, and 8.5 hours after the first dose of Polyphenon E on day 1 ]
    Clearance of Polyphenon E will be compared among cirrhotic liver patients in this study and results from this population will be compared with non-cirrhotic historical control participants.

Other Outcome Measures:
  1. Grade of cirrhosis [ Time Frame: Up to 24 weeks ]
    Will be assessed by FibroScan and Fibrosis-4 score.

  2. Liquid chromatography-mass spectrometry (LC-MS) and/or enzyme-linked immunosorbent assay (ELISA)-based method for detecting gamma-OHPdG [ Time Frame: Up to 24 weeks ]
    The research urine samples at screen 2 and research blood samples collected at visit 1, visit 2, and Visit 3 will be used to develop a non-invasive LC-MS and/or ELISA-based method to quantify gamma-OHPdG in urine and blood samples of collected from trial participants. Descriptive statistics (n; minimum [min]; maximum [max]; mean; median; standard deviation [SD] for continuous variables; and n, frequency for categorical variables) will be used to summarize participants demographics. Participants safety data will be tabulated according to the symptom and grade. Estimates will be presented with their 95% confidence intervals.

  3. Incidence of hepatocellular carcinoma [ Time Frame: At baseline and 24 weeks ]
    Evaluated using ultrasound/computed tomography (CT)/magnetic resonance imaging (MRI).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants with a clinical diagnosis of cirrhosis based on the investigators evaluation, confirmed by ANY ONE of the three following methods to define cirrhosis:

    • Established cirrhosis on liver biopsy (Meta-analysis of Histological Data in Viral Hepatitis [METAVIR] F4);
    • Ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) findings consistent with cirrhosis; nodular appearing liver with or without evidence of portal hypertension
    • Transient elastography (FibroScan) with a result > 12.5 kPa Etiology of cirrhosis will not be considered in determining inclusion in the study
  • Participant is able and willing to comply with study procedures, and signed and dated informed consent is obtained
  • Participant agrees to consume no more than 2 cups of green tea per day and refrain from taking supplements or foods labeled as containing green tea
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
  • Platelets >= 75,000 / uL
  • Hemoglobin >= 8 g/dL
  • Serum creatinine OR measured or calculated creatinine clearance within normal institutional limits; glomerular filtration rate (GFR) can also be used in place of creatinine or creatinine clearance (CrCl) within normal institutional limits as adjusted for age and sex
  • Serum direct bilirubin within normal institutional limits
  • AST (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X upper normal level (UNL)
  • Albumin >= 3.0 mg/dL
  • International normalized ratio (INR) =< 1.3
  • Ascites absent
  • Encephalopathy absent
  • Only participants found to express high levels (immunohistochemistry [IHC] score 3 and above) of gamma-OHPdG (gamma-OHPdG-high HCC) in baseline or archival liver biopsy will be registered to receive Polyphenon E treatment
  • Participant is able to undergo radiographic evaluation with ultrasound, CT, or MRI
  • The effects of Polyphenon E on the developing human fetus at the recommended therapeutic dose are unknown; for this reason,women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence); contraception must be used prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; female participants of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication (if a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required)

Exclusion Criteria:

  • Participant has confirmed HCC by ultrasound/CT/MRI; participants who have previously had HCC but have been treated and have been recurrence free for 5 years are eligible
  • Participant has or has had other cancer(s) within 3 years of study; however, in situ breast, in situ cervical, and basal cell/squamous cell skin cancers are allowed; participant with active, other cancer that requires systemic therapy will be excluded from this study; participant with early stage cancer that requires local therapy, such as cervical ablation for early stage cervical cancer, are allowed to be registered in the study and are allowed to receive local therapy
  • Inability to swallow capsules
  • Participant has a known diagnosis of mental incapacitation that may affect their ability to consent and be compliant with the protocol
  • Participant has ever experienced one or more hepatic decompensation events or a history of decompensated liver disease as listed below:

    • Clinical ascites
    • Variceal bleeding documented by endoscopy
    • Spontaneous bacterial peritonitis documented by positive culture
    • Hepatic encephalopathy
    • Hepatorenal syndrome (type 1 or 2)
    • Porto-pulmonary hypertension
    • Hepato-pulmonary hypertension
    • Any liver-related event which led to a hospitalization or a grade 4 event
  • Participant has an underlying predisposition to gastrointestinal (GI) or rectal bleeding are considered ineligible for study participation
  • History of allergic reactions attributed to compounds of similar chemical composition to Polyphenon E (or green tea); note that participants who are unable to tolerate intravenous contrast for CT scans should have MRIs or ultrasounds during the study instead of CT scans
  • Participant is receiving any other investigational agents
  • Participants have taken supplements or foods that are labelled as containing green tea for 8 weeks before start of treatment
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; hepatitis b virus (HBV) and hepatitis C virus (HCV) infections are allowed
  • Green tea has been consumed by humans for thousands of years and teratogenic or abortifacient effects have not been reported; however, subjects in this study will take high doses of Polyphenon E; the teratogenic or abortifacient effects of high dose Polyphenon E is unknown; therefore pregnant women are excluded from this study; because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with Polyphenon E, breastfeeding should be discontinued if the mother is treated with this study agent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03278925

Layout table for location information
United States, District of Columbia
MedStar Georgetown University Hospital
Washington, District of Columbia, United States, 20007
Puerto Rico
University of Puerto Rico
San Juan, Puerto Rico, 00936
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Aiwu R He Northwestern University
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03278925    
Other Study ID Numbers: NCI-2017-01557
NCI-2017-01557 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
NCI 2016-08-02 ( Other Identifier: Northwestern University )
NWU2016-08-02 ( Other Identifier: DCP )
N01CN00035 ( U.S. NIH Grant/Contract )
P30CA060553 ( U.S. NIH Grant/Contract )
First Posted: September 12, 2017    Key Record Dates
Last Update Posted: September 30, 2022
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Epigallocatechin gallate
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antimutagenic Agents
Anticarcinogenic Agents
Antineoplastic Agents
Neuroprotective Agents